Scholarlink

Background <p>Acute myeloid leukemia (AML) remains a challenging hematological malignancy with high mortality rates despite conventional chemotherapy. The Janus Kinase (JAK)/ Signal Transducer and Activator of Transcription (STAT) signaling pathway, crucial in cellular differentiation, proliferation, and apoptosis, has emerged as a promising therapeutic target in AML. This study investigates the efficacy and mechanism of SAR317461, a novel JAK/STAT inhibitor, in AML treatment.</p> Methods <p>We evaluated SAR317461’s effects on AML cell lines (THP-1 and C1498) through cell viability, apoptosis, and autophagy assays. Western blot analysis assessed JAK/STAT pathway inhibition. In vivo studies using AML mouse models examined SAR317461’s efficacy, pharmacokinetics, and biosafety.</p> Results <p>SAR317461 significantly inhibited AML cell proliferation and induced apoptosis in a dose-dependent manner. It downregulated JAK2 and STAT3 phosphorylation and stimulated autophagy in leukemic cells. In vivo, SAR317461 reduced peripheral blood leukocyte counts and prolonged survival in AML mice. Pharmacokinetic studies revealed a half-life of approximately 4&#xa0;h, with no significant organ damage or long-term toxicity observed at therapeutic doses.</p> Conclusion <p>Our findings demonstrate that SAR317461 effectively inhibits AML progression both in vitro and in vivo by targeting the JAK/STAT pathway and inducing apoptosis and autophagy. This study provides compelling evidence for the potential of SAR317461 as a novel, targeted therapy for AML, warranting further clinical investigation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

SAR317461 Inhibit JAK2/STAT3 Phosphorylation for Enhanced Anti-leukemia Activity

  • 期刊论文

  • 发表日期：

    2025年3月25日

查看全文
  • Xiao-Yu Yang,
  • Yan Wang,
  • Lin Zhang,
  • Su-Lei Pang,
  • Xiao-Jie Li,
  • Pan-Pan Wang,
  • Ruo-Jin Ma,
  • Yun-Yun Ma,
  • Chun-Ge Song

摘要

Background

Acute myeloid leukemia (AML) remains a challenging hematological malignancy with high mortality rates despite conventional chemotherapy. The Janus Kinase (JAK)/ Signal Transducer and Activator of Transcription (STAT) signaling pathway, crucial in cellular differentiation, proliferation, and apoptosis, has emerged as a promising therapeutic target in AML. This study investigates the efficacy and mechanism of SAR317461, a novel JAK/STAT inhibitor, in AML treatment.

Methods

We evaluated SAR317461’s effects on AML cell lines (THP-1 and C1498) through cell viability, apoptosis, and autophagy assays. Western blot analysis assessed JAK/STAT pathway inhibition. In vivo studies using AML mouse models examined SAR317461’s efficacy, pharmacokinetics, and biosafety.

Results

SAR317461 significantly inhibited AML cell proliferation and induced apoptosis in a dose-dependent manner. It downregulated JAK2 and STAT3 phosphorylation and stimulated autophagy in leukemic cells. In vivo, SAR317461 reduced peripheral blood leukocyte counts and prolonged survival in AML mice. Pharmacokinetic studies revealed a half-life of approximately 4 h, with no significant organ damage or long-term toxicity observed at therapeutic doses.

Conclusion

Our findings demonstrate that SAR317461 effectively inhibits AML progression both in vitro and in vivo by targeting the JAK/STAT pathway and inducing apoptosis and autophagy. This study provides compelling evidence for the potential of SAR317461 as a novel, targeted therapy for AML, warranting further clinical investigation.